ClinicalTrials.gg
TerminatedNCT00137046Updated Feb 18, 2010Results posted

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes

A Phase 3 interventional study of Subcutaneous Insulin and Inhaled Insulin in Diabetes Mellitus, Type 1, sponsored by Pfizer. Terminated at 73 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-02-18.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
582
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing insulin in Diabetes Mellitus, Type 1 — 4 open to participants now, 4 under way, none of them phase 3. Insulin · Diabetes Mellitus, Type 1.

Enrollment
3rd of 51
582 · median 20
Started
2002
the only one that year
Phase 3
7 of 51
none open now
Registered
3rd of 51
by date
Lead sponsor
3 of 51
Pfizer

Among the 51 studies testing insulin in Diabetes Mellitus, Type 1, this one is the 3rd largest by enrollment, is the only one that started in 2002, is one of 7 in phase 3, and was the 3rd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

4 of the 51 studies testing insulin in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing insulin in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This study is being done to find out the good and bad effects of a drug that is not approved for sale and the effects if any on measures of pulmonary function in adult males and females with type 1 diabetes mellitus. The drug is called EXUBERA (inhaled insulin).

This study included a 2-year comparative treatment period followed by a 6-month follow-up period during which inhaled insulin-treated subjects were switched back to subcutaneous short-acting insulin. After this follow-up period, all eligible subjects entered a comparative extension period that was to last for 5 years. When the comparative portion of the study was terminated, all subjects were requested to return for a final extension follow-up month 3 visit.

Read the detailed description

Pfizer announced in October 2007 that it would stop marketing Exubera. Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, study A2171022 was terminated on June 9, 2008. Neither safety nor efficacy reasons were the cause of the study termination.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 diabetes mellitus

Exclusion criteria

Exclusion Criteria:

  • severe asthma or
  • smoking
  • brittle diabetes
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
582 participants (actual)

Study arms

  • Active comparator
    Subcutaneous Insulin

    Drug: Subcutaneous Insulin

  • Experimental
    Inhaled Insulin

    Drug: Inhaled Insulin

Interventions

  • Subcutaneous insulin with dose adjusted according to premeal blood glucose

  • Inhaled insulin with dose adjusted according to premeal blood glucose

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Forced Expiratory Volume in One Second (FEV1)

    Change from Baseline: mean of (value of observed forced expiratory volume in the first second of forced exhalation \[FEV1\] in liters \[L\] at observation minus Baseline value).

    Time frame: Baseline through Extension Follow-up Month 3

  2. Summary of ≥ 15% Decliners in Forced Expiratory Volume in One Second (FEV1)

    Number of subjects with a post-baseline Forced Expiratory Volume in One Second (FEV1) decrease of ≥ 15 % \[(baseline observed value minus visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrent illness, a repeat FEV1 was performed.

    Time frame: Month 3 through Extension Follow-up 3

  3. Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco)

    Change from Baseline: mean of (value of Carbon Monoxide Diffusing Capacity \[DLco\] measured in milliters/minutes/millimeters of mercury \[mL/min/mmHg\] at observation minus Baseline value).

    Time frame: Baseline through Extension Follow-up Month 3

  4. Summary of ≥ 20% Decliners in Carbon Monoxide Diffusing Capacity (DLco).

    Number of subjects with a post-baseline Carbon Monoxide Diffusing Capacity (DLco) decrease of ≥ 20% \[(baseline observed value minus visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrent illness, a repeat DLco was performed.

    Time frame: Month 3 through Extension Follow-up Month 3

  5. Annual Rate of Change in Forced Expiratory Volume in 1 Second (FEV1)

    Annual rate of change in FEV1 calculated as slope over time \[visit\] for forced expiratory volume in 1 second measured as liters per year (L/yr).

    Time frame: Week -2 through Extension Follow-up Month 6 or end of study

  6. Annual Rate of Change in Carbon Monoxide Diffusion Capacity (DLco)

    Annual rate of change in DLco calculated as slope over time (visit) measured as milliliters per minute per millimeters of hemoglobin per year (ml/min/mmHg/yr).

    Time frame: Week -2 through Extension Follow-up Month 6 or end of study

Secondary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c)

    Change from Baseline: mean of (value of Glycosylated Hemoglobin \[HbA1c\] at observation minus Baseline value).

    Time frame: Baseline through Extension Follow-up Month 3

  2. Hypoglycemic Event Rates

    A Hypoglycemic event was identified by characteristic symptoms of hypoglycemia with no blood glucose check with prompt resolution with food intake, subcutaneous glucagon, or intravenouus glucose; characteristic symptoms with blood glucose of 59 milligrams per deciliter (mg/dL) (3.2 mmol/L) or less with blood glucose check; or any glucose measurement of 49 mg/dL (2.7 mmol/L) or less, with or without symptoms. Subject months = elapsed number of months a subject was in the study in each time interval. Crude event rate = total events divided by subject month of treatment.

    Time frame: Month 1 through Extension Month 39

  3. Severe Hypoglycemic Event Rates

    Severe hypoglycemic event = all 3 of the following criteria were met: subject unable to treat self, exhbited at least 1 neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, loss of consciousness); and blood glucose measurement was ≤49 mg/dL, or not measured but clinical manifestations reversed by oral carbohydrates, subcutaneous glucagon, or i.v. glucose. Subject months = elapsed number of months subject was in study in each time interval. Crude event rate = total events divided by subject months \* 100.

    Time frame: Month 1 through Extension Month 39

  4. Change From Baseline in Fasting Plasma Glucose

    Change from Baseline: mean of (value of fasting plasma glucose \[milligrams per deciliter (mg/dL)\] at observation minus Baseline value).

    Time frame: Baseline through Extension Follow-up Month 3

  5. Change From Baseline Body Weight

    Body weight: mean Baseline and change from Baseline in kilograms (kg). Change from baseline = mean body weight in kilograms (kg) at observation minus mean baseline body weight.

    Time frame: Baseline through Extension Follow-up Month 3

  6. Total Daily Long-Acting Insulin Dose (Unadjusted for Body Weight)

    Total Daily Long-Acting Insulin Dose Unadjusted for Body Weight; long-acting insulin included NPH Insulin, Ultralente, and Insulin Glargine for both groups.

    Time frame: Month 3 through Extension Month 39

  7. Total Daily Long-Acting Insulin Dose Adjusted for Body Weight

    Total daily dose of long-acting insulin adjusted for body weight (units per kilogram \[kg\]). Long-acting insulin included NPH Insulin, Ultralente, and Insulin Glargine for both groups.

    Time frame: Month 3 through Extension Month 39

  8. Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)

    Total daily dose of short-acting insulin unadjusted for body weight. Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.

    Time frame: Month 3 through Extension Month 39

  9. Total Daily Short-Acting Insulin Dose Adjusted for Body Weight

    Total Daily Short-Acting Insulin Dose adjusted for body weight (milligrams \[mg\] or units divided by kilograms \[kg\]). Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.

    Time frame: Month 3 through Extension Month 39

  10. Baseline Dyspnea Index (BDI)

    Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. BDI score range 0 (very severe impairment) to 4 (no impairment) scaled to a BDI focal score (0-12). Lower score indicates greater impairment.

    Time frame: Week - 1

  11. Transition Dyspnea Index (TDI)

    Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. TDI score range -3 (major deterioration) to +3 (major improvement); sum of all domains yields the TDI focal score (-9 to +9); lower score indicates greater deterioration. Compared to previous scoring to determine deterioration or improvement.

    Time frame: Week 4 through ,Extension Follow-up Month 6 and every 6 months thereafter or end of study

  12. Lipids

    Total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides measured as milligrams per deciliter (mg/dL).

    Time frame: Week -4 through Month 24

  13. Cough Questionnaire

    Subject completed cough questionnaire with reference to the past 4 weeks. Six question instrument to measure cough frequency (night, day), severity, timing in relation to short-acting insulin dosing, severity related to insulin dosing (subcutaneous \[SC\] or inhaled), and productivity of cough; range 0 (no symptoms) to 4 (severe symptoms). Questionnaire was administered at Week 0 and then at subsequent visits only if cough was identified as an adverse event not explained by a concomitant condition, such as an upper respiratory tract infection.

    Time frame: Week 0 and if indicated through Extension Follow up Month 3

  14. Forced Vital Capacity (FVC)

    Forced Vital Capacity (FVC) measured in liters (L).

    Time frame: Week -3 through Extension Follow-up Month 6 or End of Study

  15. Total Lung Capacity (TLC)

    Total Lung Capacity measured in liters (L).

    Time frame: Week -3 through Extension Follow-up Month 6 or End of Study

  16. Insulin Antibodies

    Median insulin antibodies at each visit measured in micro units per milliliter (microU/mL).

    Time frame: Baseline through Extension Month 39

07

Results

Posted Jan 26, 2010
Limitations and caveats
Due to early termination of study, none of the subjects completed the study as planned. Subjects active at the time of study termination completed an end-of-study assessment and a 3-month follow-up visit.

Participant flow

A total of 64 centers took part in the study between 09 May 2002 and 08 December 2008.

Participant flow — Overall Study
MilestoneInhaled InsulinSubcutaneous Insulin
Started291291
Received study treatment290290
Completed192198
Not completed9993
Withdrew: Death21
Withdrew: Adverse event165
Withdrew: Laboratory abnormality20
Withdrew: Lack of efficacy131
Withdrew: Lost to follow-up824
Withdrew: Other2319
Withdrew: Withdrawal by subject3342
Withdrew: Adverse event 4 days after last dose10
Withdrew: Withdrew prior to study treatment11

Outcome measures

PrimaryChange From Baseline in Forced Expiratory Volume in One Second (FEV1)

Change from Baseline: mean of (value of observed forced expiratory volume in the first second of forced exhalation \[FEV1\] in liters \[L\] at observation minus Baseline value).

Time frame:
Baseline through Extension Follow-up Month 3
Reported as:
Mean · liters
Change From Baseline in Forced Expiratory Volume in One Second (FEV1)
litersInhaled InsulinSubcutaneous Insulin
Baseline (n=283, 281)3.51 ± 0.763.47 ± 0.78
Month 3 (n=277, 263)-0.04 ± 0.12-0.01 ± 0.12
Month 6 (n=262, 273)-0.05 ± 0.14-0.03 ± 0.13
Month 9 (n=251, 264)-0.06 ± 0.14-0.04 ± 0.13
Month 12 (n=242, 259)-0.08 ± 0.14-004 ± 0.13
Month 15 (n=236, 250)-0.09 ± 0.16-0.05 ± 0.15
Month 18 (n=227, 232)-0.09 ± 0.15-0.06 ± 0.15
Month 21 (n=218, 224)-0.11 ± 0.16-0.06 ± 0.15
Month 24 (n=211, 219)-0.12 ± 0.17-0.08 ± 0.16
Follow-up Month 1 (n=242, 209)-0.11 ± 0.17-0.09 ± 0.16
Follow-up Month 3 (n=249, 225)-0.10 ± 0.16-0.09 ± 0.15
Follow-up Month 6 (n=240, 218)-0.10 ± 0.17-0.09 ± 0.16
Extension Month 1 (n=166, 175)-0.14 ± 0.20-0.10 ± 0.17
Extension Month 3 (n=161, 175)-0.14 ± 0.18-0.10 ± 0.18
Extension Month 6 (n=158, 170)-0.15 ± 0.19-0.11 ± 0.17
Extension Month 9 (n=151, 164)-0.16 ± 0.18-0.12 ± 0.19
Extension Month 12 (n=152,161)-0.17 ± 0.19-0.11 ± 0.16
Extension Month 15 (n=153,162)-0.16 ± 0.19-0.12 ± 0.17
Extension Month 18 (n=148,160)-0.18 ± 0.20-0.14 ± 0.19
Extension Month 21 (n=144,158)-0.17 ± 0.19-0.15 ± 0.20
Extension Month 24 (n=141,153)-0.18 ± 0.20-0.14 ± 0.20
Extension Month 27 (n=136,146)-0.19 ± 0.20-0.13 ± 0.19
Extension Month 30 (n=136,147)-0.20 ± 0.20-0.16 ± 0.19
Extension Month 33 (n=127,139)-0.20 ± 0.21-0.17 ± 0.19
Extension Month 36 (n=105,126)-0.23 ± 0.22-0.16 ± 0.18
Extension Month 39 (n=52, 64)-0.21 ± 0.23-0.17 ± 0.21
Extension Month 39 (LOCF) (n=177, 187)-0.22 ± 0.21-0.15 ± 0.19
Extension Follow Up Month 3 (n=115,102)-0.20 ± 0.20-0.17 ± 0.18
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.024 · 90% CI -0.041 to -0.007
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.022 · 90% CI -0.040 to -0.003
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.019 · 90% CI -0.038 to 0.001
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.038 · 90% CI -0.058 to -0.019
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.042 · 90% CI -0.065 to -0.020
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.020 · 90% CI -0.043 to 0.002
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.043 · 90% CI -0.066 to -0.020
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.033 · 90% CI -0.058 to -0.009
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.015 · 90% CI -0.039 to 0.009
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.005 · 90% CI -0.027 to 0.017
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.013 · 90% CI -0.037 to 0.012
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.045 · 90% CI -0.076 to -0.014
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.045 · 90% CI -0.076 to -0.013
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.040 · 90% CI -0.071 to -0.008
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.041 · 90% CI -0.074 to -0.008
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.056 · 90% CI -0.088 to -0.025
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.039 · 90% CI -0.071 to -0.007
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.044 · 90% CI -0.079 to -0.010
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.020 · 90% CI -0.055 to 0.016
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.042 · 90% CI -0.079 to -0.004
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.055 · 90% CI -0.091 to -0.019
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.045 · 90% CI -0.081 to -0.010
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.036 · 90% CI -0.073 to 0.002
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.079 · 90% CI -0.121 to -0.038
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.061 · 90% CI -0.124 to 0.003
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.066 · 90% CI -0.098 to -0.033
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.044 · 90% CI -0.085 to -0.004
PrimarySummary of ≥ 15% Decliners in Forced Expiratory Volume in One Second (FEV1)

Number of subjects with a post-baseline Forced Expiratory Volume in One Second (FEV1) decrease of ≥ 15 % \[(baseline observed value minus visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrent illness, a repeat FEV1 was performed.

Time frame:
Month 3 through Extension Follow-up 3
Reported as:
Number · participants
Summary of ≥ 15% Decliners in Forced Expiratory Volume in One Second (FEV1)
participantsInhaled InsulinSubcutaneous Insulin
Month 3 (n=277, 263)00
Month 6 (n=262, 273)00
Month 9 (n=251, 264)01
Month 12 (n=242, 259)10
Month 15 (n=236, 250)31
Month 18 (n=227, 232)03
Month 21 (n=218, 224)23
Month 24 (n=211, 219)32
Follow-up Month 1 (n=242, 209)22
Follow-up Month 3 (n=249, 225)33
Follow-up Month 6 (n=240, 218)51
Extension Month 1 (n=166, 175)22
Extension Month 3 (n=161, 175)42
Extension Month 6 (n=158, 170)22
Extension Month 9 (n=151, 164)32
Extension Month 12 (n=152, 161)20
Extension Month 15 (n=153, 162)10
Extension Month 18 (n=148, 160)43
Extension Month 21 (n=144, 158)45
Extension Month 24 (n=141, 153)35
Extension Month 27 (n=136, 146)64
Extension Month 30 (n=136, 147)62
Extension Month 33 (n=127, 139)43
Extension Month 36 (n=105, 126)73
Extension Month 39 (n=52, 64)21
Extension Follow Up Month 3 (n=115, 102)51
SecondaryChange From Baseline in Glycosylated Hemoglobin (HbA1c)

Change from Baseline: mean of (value of Glycosylated Hemoglobin \[HbA1c\] at observation minus Baseline value).

Time frame:
Baseline through Extension Follow-up Month 3
Reported as:
Mean · percent
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
percentInhaled InsulinSubcutaneous Insulin
Baseline (n=288, 286)7.41 ± 1.067.46 ± 1.06
Week 6 (n=269, 256)-0.40 ± 0.61-0.43 ± 0.61
Month 3 (n=276, 280)-0.36 ± 0.78-0.41 ± 0.73
Month 6 (n=263, 274)-0.21 ± 0.80-0.36 ± 0.81
Month 9 (n=253, 266)-0.10 ± 0.84-0.23 ± 0.81
Month 12 (n=240, 262)-0.04 ± 0.87-0.32 ± 0.82
Month 15 (n=236, 253)-0.12 ± 0.85-0.29 ± 0.90
Month 18 (n=231, 237)-0.11 ± 0.88-0.30 ± 0.89
Month 21 (n=223, 231)-0.05 ± 0.92-0.25 ± 0.92
Month 24 (n=214, 225)0.05 ± 0.91-0.27 ± 0.83
Follow-up Month 3 (n=205, 195)-0.13 ± 0.87-0.22 ± 0.83
Follow-up Month 6 (n=219, 221)-0.10 ± 0.87-0.14 ± 0.87
Extension Month 1 (n=171, 177)-0.09 ± 0.90-0.23 ± 0.85
Extension Month 3 (n=170, 177)0.12 ± 0.95-0.17 ± 0.91
Extension Month 6 (n=166, 178)0.21 ± 0.99-0.19 ± 0.86
Extension Month 9 (n=159, 171)0.26 ± 1.00-0.06 ± 0.94
Extension Month 12 (n=158, 169)0.39 ± 0.980.08 ± 0.87
Extension Month 15 (n=156, 167)0.40 ± 1.050.17 ± 0.85
Extension Month 18 (n=153, 166)0.32 ± 0.940.05 ± 0.86
Extension Month 21 (n=154, 161)0.27 ± 0.990.00 ± 0.88
Extension Month 24 (n=149, 154)0.29 ± 0.890.06 ± 0.91
Extension Month 27 (n=141, 151)0.33 ± 0.970.10 ± 0.92
Extension Month 30 (n=140, 150)0.33 ± 0.91-0.01 ± 0.89
Extension Month 33 (n=131, 143)0.40 ± 0.94-0.08 ± 0.92
Extension Month 36 (n=108, 132)0.30 ± 0.99-0.03 ± 0.99
Extension Month 39 (n=55, 66)0.30 ± 0.94-0.09 ± 1.00
Extension Follow-Up Month 3 (n=120, 107)0.14 ± 1.000.12 ± 1.00
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.031 · 90% CI -0.060 to 0.122
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.136 · 90% CI 0.033 to 0.239
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.112 · 90% CI -0.000 to 0.224
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.257 · 90% CI 0.141 to 0.374
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.156 · 90% CI 0.040 to 0.273
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.182 · 90% CI 0.065 to 0.300
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.190 · 90% CI 0.060 to 0.319
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.316 · 90% CI 0.190 to 0.443
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.093 · 90% CI -0.037 to 0.224
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.021 · 90% CI -0.103 to 0.145
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.112 · 90% CI -0.023 to 0.248
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.273 · 90% CI 0.126 to 0.419
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.363 · 90% CI 0.219 to 0.507
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.278 · 90% CI 0.128 to 0.428
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.293 · 90% CI 0.144 to 0.442
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.213 · 90% CI 0.058 to 0.369
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.243 · 90% CI 0.101 to 0.386
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.227 · 90% CI 0.079 to 0.376
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.225 · 90% CI 0.079 to 0.372
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.211 · 90% CI 0.055 to 0.368
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.331 · 90% CI 0.180 to 0.483
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.462 · 90% CI 0.302 to 0.622
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.410 · 90% CI 0.221 to 0.600
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.451 · 90% CI 0.183 to 0.718
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.032 · 90% CI -0.174 to 0.237
SecondaryHypoglycemic Event Rates

A Hypoglycemic event was identified by characteristic symptoms of hypoglycemia with no blood glucose check with prompt resolution with food intake, subcutaneous glucagon, or intravenouus glucose; characteristic symptoms with blood glucose of 59 milligrams per deciliter (mg/dL) (3.2 mmol/L) or less with blood glucose check; or any glucose measurement of 49 mg/dL (2.7 mmol/L) or less, with or without symptoms. Subject months = elapsed number of months a subject was in the study in each time interval. Crude event rate = total events divided by subject month of treatment.

Time frame:
Month 1 through Extension Month 39
Reported as:
Number · total events/subject months
Hypoglycemic Event Rates
total events/subject monthsInhaled InsulinSubcutaneous Insulin
Month 1 (n=288, 286)7.66.3
Month 2 (n=282, 286)5.95.5
Month 3 (n=279, 285)5.85.3
Month 4 (n=273, 282)4.84.6
Month 5 (n=266, 280)4.74.4
Month 6 (n=263, 277)4.54.2
Month 7 (n=259, 275)4.54.3
Month 8 (n=257, 273)4.23.8
Month 9 (n=254, 272)3.83.7
Month 10 (n=249, 270)4.23.9
Month 11 (n=245, 269)3.93.4
Month 12 (n=243, 267)3.83.8
Month 13 (n=239, 265)3.63.5
Month 14 (n=237, 260)3.63.6
Month 15 (n=236, 258)3.23.3
Month 16 (n=236, 256)3.43.5
Month 17 (n=235, 252)3.03.1
Month 18 (n=233, 250)3.03.1
Month 19 (n=232, 250)3.23.0
Month 20 (n=227, 245)3.03.2
Month 21 (n=226, 244)3.03.0
Month 22 (n=226, 243)2.83.1
Month 23 (n=224, 238)2.52.9
Month 24 (n=222, 229)2.62.5
Extension Month 1 (n=177, 187)3.52.9
Extension Month 2 (n=177, 187)3.62.7
Extension Month 3 (n=172, 185)4.12.9
Extension Month 4 (n=169, 182)3.22.6
Extension Month 5 (n=169, 182)3.22.8
Extension Month 6 (n=168, 182)2.82.5
Extension Month 7 (n=167, 181)3.12.5
Extension Month 8 (n=167, 178)2.62.8
Extension Month 9 (n=165, 177)2.12.6
Extension Month 10 (n=165, 176)3.12.6
Extension Month 11 (n=162, 175)3.22.2
Extension Month 12 (n=160, 175)3.32.5
Extension Month 13 (n=158, 174)2.82.6
Extension Month 14 (n=156, 173)2.92.7
Extension Month 15 (n=156, 173)3.02.3
Extension Month 16 (n=156, 172)3.42.4
Extension Month 17 (n=156, 172)3.02.3
Extension Month 18 (n=156, 172)3.02.2
Extension Month 19 (n=155, 172)3.22.6
Extension Month 20 (n=155, 170)2.92.1
Extension Month 21 (n=155, 169)2.82.3
Extension Month 22 (n=155, 165)2.82.2
Extension Month 23 (n=152, 164)3.32.3
Extension Month 24 (n=152, 163)2.92.1
Extension Month 25 (n=150, 162)3.22.1
Extension Month 26 (n=149, 160)2.72.1
Extension Month 27 (n=147, 159)2.71.9
Extension Month 28 (n=146, 158)2.72.3
Extension Month 29 (n=145, 155)2.72.0
Extension Month 30 (n=143, 153)2.51.9
Extension Month 31 (n=141, 153)2.62.2
Extension Month 32 (n=138, 152)2.82.1
Extension Month 33 (n=136, 150)2.32.1
Extension Month 34 (n=131, 148)2.02.1
Extension Month 35 (n=122, 147)1.82.1
Extension Month 36 (n=113, 138)1.92.4
Extension Month 37 (n=88, 104)1.52.0
Extension Month 38 (n=66, 73)1.81.7
Extension Month 39 (n=53, 64)1.71.4
Overall Comparative (n=288, 286)4.13.9
Overall Extension (n=177, 187)2.82.4
SecondarySevere Hypoglycemic Event Rates

Severe hypoglycemic event = all 3 of the following criteria were met: subject unable to treat self, exhbited at least 1 neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, loss of consciousness); and blood glucose measurement was ≤49 mg/dL, or not measured but clinical manifestations reversed by oral carbohydrates, subcutaneous glucagon, or i.v. glucose. Subject months = elapsed number of months subject was in study in each time interval. Crude event rate = total events divided by subject months \* 100.

Time frame:
Month 1 through Extension Month 39
Reported as:
Number · events / subject months * 100
Severe Hypoglycemic Event Rates
events / subject months * 100Inhaled InsulinSubcutaneous Insulin
Month 1 (n=288, 286)10.29.1
Month 2 (n=282, 286)7.97.4
Month 3 (n=279, 285)6.56.0
Month 4 (n=273, 282)3.44.3
Month 5 (n=266, 280)0.04.3
Month 6 (n=263, 277)3.86.5
Month 7 (n=259, 275)2.34.0
Month 8 (n=257, 273)2.04.0
Month 9 (n=254, 272)4.05.2
Month 10 (n=249, 270)0.83.3
Month 11 (n=245, 269)2.13.0
Month 12 (n=243, 267)2.53.8
Month 13 (n=239, 265)1.32.7
Month 14 (n=237, 260)1.33.5
Month 15 (n=236, 258)1.73.1
Month 16 (n=236, 256)2.62.0
Month 17 (n=235, 252)3.91.6
Month 18 (n=233, 250)2.65.6
Month 19 (n=232, 250)0.42.4
Month 20 (n=227, 245)0.44.9
Month 21 (n=226, 244)1.82.9
Month 22 (n=226, 243)0.92.1
Month 23 (n=224, 238)0.92.6
Month 24 (n=222, 239)0.82.6
Extension Month 1 (n=177, 187)3.91.2
Extension Month 2 (n=177, 187)4.07.0
Extension Month 3 (n=172, 185)4.02.4
Extension Month 4 (n=169, 182)1.41.2
Extension Month 5 (n=169, 182)2.74.2
Extension Month 6 (n=168, 182)0.03.0
Extension Month 7 (n=167, 181)0.72.4
Extension Month 8 (n=167, 178)0.02.4
Extension Month 9 (n=165, 177)2.14.9
Extension Month 10 (n=165, 176)0.03.0
Extension Month 11 (n=162, 175)2.81.2
Extension Month 12 (n=160, 175)1.44.3
Extension Month 13 (n=158, 174)0.71.8
Extension Month 14 (n=156, 173)1.43.1
Extension Month 15 (n=156, 173)1.411.1
Extension Month 16 (n=156, 172)0.713.7
Extension Month 17 (n=156, 172)0.75.6
Extension Month 18 (n=156, 172)0.07.5
Extension Month 19 (n=155, 172)1.46.9
Extension Month 20 (n=155, 170)2.12.5
Extension Month 21 (n=155, 169)1.43.8
Extension Month 22 (n=155, 165)2.11.3
Extension Month 23 (n=152, 164)1.43.2
Extension Month 24 (n=152, 163)0.73.2
Extension Month 25 (n=150, 162)1.50.0
Extension Month 26 (n=149, 160)2.20.7
Extension Month 27 (n=147, 159)0.70.0
Extension Month 28 (n=146, 158)0.03.4
Extension Month 29 (n=145, 155)0.00.7
Extension Month 30 (n=143, 153)0.80.7
Extension Month 31 (n=141, 153)3.10.0
Extension Month 32 (n=138, 152)0.01.4
Extension Month 33 (n=136, 150)2.41.4
Extension Month 34 (n=131, 148)0.81.4
Extension Month 35 (n=122, 147)0.05.9
Extension Month 36 (n=113, 138)1.00.9
Extension Month 37 (n=88, 104)0.03.8
Extension Month 38 (n=66, 73)0.00.0
Extension Month 39 (n=53, 64)0.81.7
Overall Comparative (n=288, 286)2.84.1
Overall Extension (n=177, 187)1.43.3
SecondaryChange From Baseline in Fasting Plasma Glucose

Change from Baseline: mean of (value of fasting plasma glucose \[milligrams per deciliter (mg/dL)\] at observation minus Baseline value).

Time frame:
Baseline through Extension Follow-up Month 3
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose
mg/dLInhaled InsulinSubcutaneous Insulin
Baseline (n=286, 286)171.24 ± 63.20170.06 ± 55.20
Week 6 (n=263, 250)-26.04 ± 84.79-14.02 ± 80.13
Month 3 (n=267, 276)-21.84 ± 85.26-6.15 ± 79.08
Month 6 (n=258, 271)-31.48 ± 81.62-6.29 ± 83.81
Month 9 (n=243, 262)-25.34 ± 86.241.28 ± 96.32
Month 12 (n=232, 256)-24.25 ± 87.53-4.95 ± 85.96
Month 15 (n=230, 251)-34.75 ± 83.725.96 ± 89.39
Month 18 (n=226, 236)-24.13 ± 86.44-8.13 ± 88.83
Month 21 (n=216, 230)-26.77 ± 88.96-11.62 ± 82.98
Month 24 (n=208, 222)-18.36 ± 92.921.25 ± 84.87
Follow-up Month 3 (n=2, 2)-43.50 ± 85.0946.67 ± 24.04
Follow-up Month 6 (n=159, 164)3.45 ± 80.261.46 ± 85.49
Extension Month 1 (n=164, 171)-25.52 ± 90.15-2.72 ± 91.27
Extension Month 3 (n=167, 172)-25.02 ± 87.750.43 ± 84.55
Extension Month 6 (n=164, 177)-13.47 ± 80.85-12.56 ± 86.93
Extension Month 9 (n=152, 170)-16.19 ± 94.12-4.46 ± 88.86
Extension Month 12 (n=155, 167)-22.53 ± 83.01-5.15 ± 81.38
Extension Month 15 (n=148, 163)-26.11 ± 85.78-10.64 ± 86.00
Extension Month 18 (n=148, 163)-12.42 ± 86.69-2.32 ± 84.41
Extension Month 21 (n=152, 157)-24.75 ± 87.294.86 ± 89.31
Extension Month 24 (n=142, 148)-20.46 ± 86.45-10.36 ± 93.08
Extension Month 27 (n=140, 148)-14.91 ± 78.42-2.86 ± 91.97
Extension Month 30 (n=138, 147)-17.16 ± 86.47-3.77 ± 86.15
Extension Month 33 (n=129, 141)-22.77 ± 94.77-12.12 ± 88.26
Extension Month 36 (n=107, 132)-20.00 ± 81.03-2.49 ± 86.06
Extension Month 39 (n=55, 64)-38.47 ± 95.17-1.57 ± 78.47
Extension Follow-Up Month 3 (n=118, 105)1.97 ± 95.393.25 ± 84.53
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -14.81 · 90% CI -25.24 to -4.39
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -24.83 · 90% CI -35.16 to -14.51
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -26.16 · 90% CI -37.56 to -14.75
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -19.46 · 90% CI -30.56 to -8.36
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -39.97 · 90% CI -50.93 to -29.00
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -16.08 · 90% CI -27.65 to -4.51
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -13.54 · 90% CI -24.69 to -2.39
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -18.86 · 90% CI -30.88 to -6.84
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 3.56 · 90% CI -9.83 to 16.96
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -17.80 · 90% CI -31.32 to -4.27
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -20.71 · 90% CI -33.44 to -7.99
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 1.80 · 90% CI -11.06 to 14.66
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -8.72 · 90% CI -23.61 to 6.17
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -16.34 · 90% CI -29.28 to -3.40
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -12.99 · 90% CI -26.60 to 0.63
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -10.22 · 90% CI -24.39 to 3.94
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -28.64 · 90% CI -43.19 to -14.09
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -8.99 · 90% CI -23.69 to 5.71
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -9.52 · 90% CI -24.04 to 5.00
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -10.40 · 90% CI -24.71 to 3.92
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -6.17 · 90% CI -21.42 to 9.09
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -5.39 · 90% CI -20.98 to 10.21
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -15.58 · 90% CI -38.43 to 7.26
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 2.84 · 90% CI -15.79 to 21.46
SecondaryChange From Baseline Body Weight

Body weight: mean Baseline and change from Baseline in kilograms (kg). Change from baseline = mean body weight in kilograms (kg) at observation minus mean baseline body weight.

Time frame:
Baseline through Extension Follow-up Month 3
Reported as:
Mean · kilograms
Change From Baseline Body Weight
kilogramsInhaled InsulinSubcutaneous Insulin
Baseline (n=288, 286)75.12 ± 13.5773.72 ± 13.13
Week 4 (n=257, 247)0.30 ± 1.390.63 ± 3.01
Week 8 (n=263, 262)0.46 ± 1.880.67 ± 2.00
Month 3 (n=273, 269)0.13 ± 2.200.67 ± 2.35
Week 18 (n=248, 260)0.15 ± 2.601.00 ± 2.64
Month 6 (n=259, 272)0.11 ± 2.891.25 ± 3.08
Month 9 (n=251, 266)0.05 ± 3.281.41 ± 3.35
Month 12 (n=242, 259)0.37 ± 3.461.55 ± 3.59
Month 15 (n=236, 250)0.44 ± 3.571.84 ± 3.90
Month 18 (n=227, 233)0.57 ± 3.992.26 ± 4.30
Month 21 (n=220, 224)1.07 ± 4.222.35 ± 4.51
Month 24 (n=211, 220)0.99 ± 4.582.23 ± 4.58
Follow-up Month 3 (n=248, 225)1.50 ± 4.242.31 ± 4.89
Follow-up Month 6 (n=239, 219)1.68 ± 4.282.17 ± 4.46
Extension Month 1 (n=166, 175)2.44 ± 6.982.50 ± 4.93
Extension Month 3 (n=161, 175)1.73 ± 4.693.08 ± 7.17
Extension Month 6 (n=158, 170)1.67 ± 4.933.05 ± 4.75
Extension Month 9 (n=153, 164)1.61 ± 4.733.17 ± 5.27
Extension Month 12 (n=152, 162)2.11 ± 4.953.08 ± 4.93
Extension Month 15 (n=153, 162)2.01 ± 5.063.16 ± 5.21
Extension Month 18 (n=149, 160)2.31 ± 5.503.30 ± 5.82
Extension Month 21 (n=144, 158)2.14 ± 5.633.72 ± 5.82
Extension Month 24 (n=141, 153)2.49 ± 5.984.23 ± 5.70
Extension Month 27 (n=136, 146)2.12 ± 5.873.96 ± 6.15
Extension Month 30 (n=136, 147)2.42 ± 6.254.80 ± 8.38
Extension Month 33 (n=127, 139)2.30 ± 5.965.28 ± 10.84
Extension Month 36 (n=105, 126)2.11 ± 6.243.87 ± 6.25
Extension Month 39 (n=52, 64)1.58 ± 7.904.83 ± 6.75
Extension Follow-Up Month 3 (n=116, 103)2.49 ± 5.984.09 ± 6.34
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.523 · 90% CI -0.846 to -0.199
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.113 · 90% CI -1.541 to -0.685
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.359 · 90% CI -1.836 to -0.882
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.184 · 90% CI -1.702 to -0.666
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.426 · 90% CI -1.984 to -0.869
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.717 · 90% CI -2.350 to -1.084
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.273 · 90% CI -1.950 to -0.596
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.069 · 90% CI -1.792 to -0.346
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.785 · 90% CI -1.475 to -0.096
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.445 · 90% CI -1.114 to 0.224
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.054 · 90% CI -1.133 to 1.025
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.336 · 90% CI -2.438 to -0.235
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.462 · 90% CI -2.356 to -0.568
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.385 · 90% CI -2.316 to -0.454
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.955 · 90% CI -1.877 to -0.034
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.000 · 90% CI -1.970 to -0.030
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.960 · 90% CI -2.041 to 0.121
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.667 · 90% CI -2.770 to -0.565
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.872 · 90% CI -3.013 to -0.730
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.887 · 90% CI -3.084 to -0.690
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -2.794 · 90% CI -4.264 to -1.324
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -3.287 · 90% CI -5.088 to -1.485
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.486 · 90% CI -2.901 to -0.071
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -3.131 · 90% CI -5.382 to -0.880
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.487 · 90% CI -2.918 to -0.055
SecondaryTotal Daily Long-Acting Insulin Dose (Unadjusted for Body Weight)

Total Daily Long-Acting Insulin Dose Unadjusted for Body Weight; long-acting insulin included NPH Insulin, Ultralente, and Insulin Glargine for both groups.

Time frame:
Month 3 through Extension Month 39
Reported as:
Mean · units
Total Daily Long-Acting Insulin Dose (Unadjusted for Body Weight)
unitsInhaled InsulinSubcutaneous Insulin
Month 3 (n=280, 285)30.52 ± 16.0034.97 ± 17.38
Month 6 (n=271, 280)30.57 ± 16.4835.37 ± 17.72
Month 9 (n=256, 269)30.69 ± 16.5335.35 ± 18.06
Month 12 (n=243, 262)30.65 ± 17.2935.42 ± 18.00
Month 15 (n=237, 255)30.99 ± 17.8335.75 ± 17.86
Month 18 (n=234, 242)30.97 ± 17.8636.35 ± 18.13
Month 21 (n=224, 233)31.30 ± 18.5336.75 ± 17.76
Month 24 (n=218, 229)31.82 ± 19.3636.21 ± 18.02
Extension Month 1 (n=171, 178)32.84 ± 18.9035.67 ± 18.72
Extension Month 3 (n=170, 177)32.45 ± 18.9135.10 ± 18.07
Extension Month 6 (n=166, 179)31.96 ± 18.3634.75 ± 17.55
Extension Month 9 (n=160, 174)32.73 ± 19.2435.22 ± 17.41
Extension Month 12 (n=159, 169)32.29 ± 19.1233.82 ± 15.65
Extension Month 15 (n=156, 164)32.02 ± 18.6135.52 ± 18.37
Extension Month 18 (n=152, 166)32.37 ± 18.6234.88 ± 17.44
Extension Month 21 (n=154, 165)31.83 ± 19.0535.14 ± 17.24
Extension Month 24 (n=150, 153)31.99 ± 19.5935.61 ± 18.34
Extension Month 27 (n=142, 153)31.25 ± 19.0135.58 ± 18.42
Extension Month 30 (n=141, 148)31.06 ± 19.7335.34 ± 18.73
Extension Month 33 (n=133, 144)30.71 ± 19.0634.83 ± 17.47
Extension Month 36 (n=113, 136)29.62 ± 19.0633.58 ± 15.64
Extension Month 39 (n=57, 67)29.07 ± 16.5933.63 ± 19.79
SecondaryTotal Daily Long-Acting Insulin Dose Adjusted for Body Weight

Total daily dose of long-acting insulin adjusted for body weight (units per kilogram \[kg\]). Long-acting insulin included NPH Insulin, Ultralente, and Insulin Glargine for both groups.

Time frame:
Month 3 through Extension Month 39
Reported as:
Mean · units/kg
Total Daily Long-Acting Insulin Dose Adjusted for Body Weight
units/kgInhaled InsulinSubcutaneous Insulin
Month 3 (n=280, 285)0.41 ± 0.220.48 ± 0.25
Month 6 (n=271, 280)0.41 ± 0.230.49 ± 0.25
Month9 (n=256, 269)0.41 ± 0.230.49 ± 0.26
Month 12 (n=243, 262)0.41 ± 0.240.49 ± 0.26
Month 15 (n=237, 255)0.42 ± 0.250.49 ± 0.25
Month 18 (n=234, 242)0.42 ± 0.250.50 ± 0.26
Month 21 (n=224, 233)0.42 ± 0.260.51 ± 0.26
Month 24 (n=218, 229)0.43 ± 0.270.50 ± 0.26
Extension Month 1 (n=171, 178)0.45 ± 0.250.49 ± 0.27
Extension Month 3 (n=170, 177)0.44 ± 0.250.49 ± 0.26
Extension Month 6 (n=166, 179)0.43 ± 0.240.48 ± 0.26
Extension Month 9 (n=160, 174)0.44 ± 0.250.49 ± 0.25
Extension Month 12 (n=159, 169)0.44 ± 0.240.47 ± 0.22
Extension Month 15 (n=156, 164)0.44 ± 0.250.49 ± 0.26
Extension Month 18 (n=152, 166)0.44 ± 0.250.48 ± 0.24
Extension Month 21 (n=154, 165)0.44 ± 0.250.48 ± 0.23
Extension Month 24 (n=150, 153)0.44 ± 0.260.49 ± 0.25
Extension Month 27 (n=142, 153)0.43 ± 0.240.49 ± 0.24
Extension Month 30 (n=141, 148)0.42 ± 0.260.49 ± 0.26
Extension Month 33 (n=133, 144)0.42 ± 0.250.48 ± 0.23
Extension Month 36 (n=113, 136)0.40 ± 0.250.46 ± 0.21
Extension Month 39 (n=57, 67)0.39 ± 0.230.45 ± 0.25
SecondaryTotal Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)

Total daily dose of short-acting insulin unadjusted for body weight. Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.

Time frame:
Month 3 through Extension Month 39
Reported as:
Mean · mg, units
Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)
mg, unitsInhaled Insulin (mg)Subcutaneous Insulin (Units)
Month 3 (n=280, 285)10.45 ± 5.7125.05 ± 14.73
Month 6 (n=271, 281)11.50 ± 6.7325.14 ± 14.72
Month 9 (n=257, 271)11.97 ± 6.7924.90 ± 14.54
Month 12 (n=243, 266)12.69 ± 6.9625.32 ± 14.35
Month 15 (n=237, 255)13.12 ± 7.6525.11 ± 14.83
Month 18 (n=234, 241)13.60 ± 8.0425.20 ± 15.15
Month 21 (n=224, 235)14.42 ± 8.6425.45 ± 15.41
Month 24 (n=219, 232)14.61 ± 9.1425.23 ± 16.57
Extension Month 1 (n=170, 179)11.49 ± 6.3525.84 ± 17.48
Extension Month 3 (n=170, 178)12.50 ± 6.8825.94 ± 18.26
Extension Month 6 (n=166, 179)13.64 ± 9.0725.39 ± 17.52
Extension Month 9 (n=160, 174)14.06 ± 9.3326.19 ± 18.00
Extension Month 12 (n=159, 169)14.74 ± 10.0725.49 ± 17.69
Extension Month 15 (n=156, 167)13.93 ± 8.3825.80 ± 17.62
Extension Month 18 (n=153, 167)13.97 ± 8.5826.04 ± 17.52
Extension Month 21 (n=154, 166)14.53 ± 8.8025.95 ± 17.04
Extension Month 24 (n=150, 156)14.48 ± 8.7127.26 ± 19.48
Extension Month 27 (n=142, 153)14.82 ± 8.7026.63 ± 17.82
Extension Month 30 (n=141, 149)14.92 ± 8.9327.22 ± 18.66
Extension Month 33 (n=133, 144)15.28 ± 9.7226.71 ± 18.67
Extension Month 36 (n=113, 136)15.72 ± 8.3227.04 ± 19.65
Extension Month 39 (n=57, 67)17.92 ± 12.0429.75 ± 19.68
SecondaryTotal Daily Short-Acting Insulin Dose Adjusted for Body Weight

Total Daily Short-Acting Insulin Dose adjusted for body weight (milligrams \[mg\] or units divided by kilograms \[kg\]). Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.

Time frame:
Month 3 through Extension Month 39
Reported as:
Mean · mg/kg, units/kg
Total Daily Short-Acting Insulin Dose Adjusted for Body Weight
mg/kg, units/kgInhaled Insulin (mg/kg)Subcutaneous Insulin (Units/kg)
Month 3 (n=280, 285)0.14 ± 0.070.34 ± 0.19
Month 6 (n=271, 281)0.15 ± 0.080.34 ± 0.19
Month 9 (n=257, 271)0.16 ± 0.090.34 ± 0.18
Month 12 (n=243, 266)0.17 ± 0.090.34 ± 0.18
Month 15 (n=237, 255)0.17 ± 0.100.34 ± 0.19
Month 18 (n=234, 241)0.18 ± 0.100.34 ± 0.19
Month 21 (n=224, 235)0.19 ± 0.110.34 ± 0.20
Month 24 (n=219, 232)0.19 ± 0.120.34 ± 0.21
Extension Month 1 (n=170, 179)0.15 ± 0.080.35 ± 0.22
Extension Month 3 (n=170, 178)0.17 ± 0.080.35 ± 0.23
Extension Month 6 (n=166, 179)0.18 ± 0.100.34 ± 0.22
Extension Month 9 (n=160, 174)0.19 ± 0.110.35 ± 0.22
Extension Month 12 (n=159, 169)0.20 ± 0.130.34 ± 0.22
Extension Month 15 (n=156, 167)0.19 ± 0.100.35 ± 0.22
Extension Month 18 (n=153, 167)0.19 ± 0.100.35 ± 0.22
Extension Month 21 (n=154, 166)0.19 ± 0.110.35 ± 0.22
Extension Month 24 (n=150, 156)0.20 ± 0.110.36 ± 0.24
Extension Month 27 (n=142, 153)0.20 ± 0.110.36 ± 0.23
Extension Month 30 (n=141, 149)0.20 ± 0.110.37 ± 0.24
Extension Month 33 (n=133, 144)0.20 ± 0.120.36 ± 0.24
Extension Month 36 (n=113, 136)0.21 ± 0.110.36 ± 0.25
Extension Month 39 (n=57, 67)0.23 ± 0.140.39 ± 0.23
SecondaryBaseline Dyspnea Index (BDI)

Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. BDI score range 0 (very severe impairment) to 4 (no impairment) scaled to a BDI focal score (0-12). Lower score indicates greater impairment.

Time frame:
Week - 1
Reported as:
Mean · scores on scale

No measurements were reported for this outcome.

SecondaryTransition Dyspnea Index (TDI)

Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. TDI score range -3 (major deterioration) to +3 (major improvement); sum of all domains yields the TDI focal score (-9 to +9); lower score indicates greater deterioration. Compared to previous scoring to determine deterioration or improvement.

Time frame:
Week 4 through ,Extension Follow-up Month 6 and every 6 months thereafter or end of study
Reported as:
Mean · scores on scale

No measurements were reported for this outcome.

SecondaryLipids

Total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides measured as milligrams per deciliter (mg/dL).

Time frame:
Week -4 through Month 24
Reported as:
Mean · mg/dL

No measurements were reported for this outcome.

SecondaryCough Questionnaire

Subject completed cough questionnaire with reference to the past 4 weeks. Six question instrument to measure cough frequency (night, day), severity, timing in relation to short-acting insulin dosing, severity related to insulin dosing (subcutaneous \[SC\] or inhaled), and productivity of cough; range 0 (no symptoms) to 4 (severe symptoms). Questionnaire was administered at Week 0 and then at subsequent visits only if cough was identified as an adverse event not explained by a concomitant condition, such as an upper respiratory tract infection.

Time frame:
Week 0 and if indicated through Extension Follow up Month 3
Reported as:
Mean · scores on scale

No measurements were reported for this outcome.

PrimaryChange From Baseline in Carbon Monoxide Diffusion Capacity (DLco)

Change from Baseline: mean of (value of Carbon Monoxide Diffusing Capacity \[DLco\] measured in milliters/minutes/millimeters of mercury \[mL/min/mmHg\] at observation minus Baseline value).

Time frame:
Baseline through Extension Follow-up Month 3
Reported as:
Mean · mL/min/mmHg
Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco)
mL/min/mmHgInhaled InsulinSubcutaneous Insulin
Baseline (n=283, 281)28.09 ± 6.2027.18 ± 6.40
Month 3 (n=277, 264)-1.09 ± 1.73-0.29 ± 1.71
Month 6 (n=262, 273)-1.17 ± 2.16-0.26 ± 1.85
Month 9 (n=250, 266)-1.16 ± 2.09-0.41 ± 1.91
Month 12 (n=241, 258)-1.40 ± 2.15-0.41 ± 2.15
Month 15 (n=235, 249)-1.16 ± 2.17-0.42 ± 2.17
Month 18 (n=227, 232)-1.21 ± 2.28-0.45 ± 2.22
Month 21 (n=218, 224)-1.29 ± 2.49-0.56 ± 2.07
Month 24 (n=208, 219)-1.28 ± 2.29-0.71 ± 2.40
Follow-up Month 1 (n=242,208)-0.81 ± 2.20-0.81 ± 2.42
Follow-up Month 3 (n=247,225)-0.77 ± 2.46-0.80 ± 2.10
Follow-up Month 6 (n=240,218)-0.77 ± 2.36-0.67 ± 2.28
Extension Month 1 (n=166,175)-1.15 ± 2.54-0.55 ± 2.35
Extension Month 3 (n=161,173)-1.43 ± 2.37-0.73 ± 2.45
Extension Month 6 (n=158,169)-1.38 ± 2.37-0.78 ± 2.54
Extension Month 9 (n=151,163)-1.17 ± 2.52-0.74 ± 2.57
Extension Month 12 (n=152,161)-1.70 ± 2.46-0.70 ± 2.60
Extension Month 15 (n=143,160)-1.70 ± 2.27-0.72 ± 2.94
Extension Month 18 (n=148,159)-1.67 ± 2.36-1.02 ± 2.72
Extension Month 21 (n=144,156)-1.51 ± 2.59-0.88 ± 2.64
Extension Month 24 (n=140,152)-1.63 ± 2.46-0.70 ± 2.72
Extension Month 27 (n=136,144)-1.25 ± 2.65-0.76 ± 2.75
Extension Month 30 (n=135,146)-1.36 ± 2.54-0.75 ± 2.59
Extension Month 33 (n=127,139)-1.31 ± 2.54-0.81 ± 2.55
Extension Month 36 (n=105,122)-1.53 ± 2.53-0.96 ± 2.82
Extension Month 39 (n=52, 64)-2.02 ± 3.72-0.93 ± 2.59
Extension Month 39 (LOCF) (n=177, 187)-1.66 ± 2.90-0.90 ± 2.55
Extension Follow Up Month 3 (n=115, 101)-0.89 ± 2.35-1.11 ± 2.59
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.744 · 90% CI -0.981 to -0.506
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.797 · 90% CI -1.073 to -0.522
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.667 · 90% CI -0.949 to -0.384
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.826 · 90% CI -1.123 to -0.528
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.610 · 90% CI -0.923 to -0.296
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.577 · 90% CI -0.910 to -0.245
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.613 · 90% CI -0.962 to -0.263
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.385 · 90% CI -0.736 to -0.034
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.150 · 90% CI -0.197 to 0.497
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.166 · 90% CI -0.160 to 0.492
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): 0.069 · 90% CI -0.274 to 0.411
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.460 · 90% CI -0.876 to -0.043
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.579 · 90% CI -0.986 to -0.172
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.460 · 90% CI -0.880 to -0.040
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.385 · 90% CI -0.822 to 0.053
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.930 · 90% CI -1.372 to -0.487
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.823 · 90% CI -1.296 to -0.351
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.525 · 90% CI -0.965 to -0.084
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.647 · 90% CI -1.104 to -0.191
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.853 · 90% CI -1.340 to -0.367
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.390 · 90% CI -0.890 to 0.111
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.636 · 90% CI -1.119 to -0.153
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.522 · 90% CI -1.000 to -0.043
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.744 · 90% CI -1.315 to -0.173
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -1.378 · 90% CI -2.420 to -0.335
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.720 · 90% CI -1.183 to -0.258
  • Inhaled Insulin vs Subcutaneous Insulin · ANCOVA · Mean difference (final values): -0.061 · 90% CI -0.594 to 0.472
PrimarySummary of ≥ 20% Decliners in Carbon Monoxide Diffusing Capacity (DLco).

Number of subjects with a post-baseline Carbon Monoxide Diffusing Capacity (DLco) decrease of ≥ 20% \[(baseline observed value minus visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrent illness, a repeat DLco was performed.

Time frame:
Month 3 through Extension Follow-up Month 3
Reported as:
Number · participants
Summary of ≥ 20% Decliners in Carbon Monoxide Diffusing Capacity (DLco).
participantsInhaled InsulinSubcutaneous Insulin
Month 3 (n=277, 264)01
Month 6 (n=262, 273)10
Month 9 (n=250, 266)21
Month 12 (n=241, 258)21
Month 15 (n=235, 249)12
Month 18 (n=227, 232)54
Month 21 (n=218, 224)42
Month 24 (n=208, 219)22
Follow-up Month 1 (n=242, 208)33
Follow-up Month 3 (n=247, 225)11
Follow-up Month 6 (n=240, 218)12
Extension Month 1 (n=166, 175)50
Extension Month 3 (n=161, 173)41
Extension Month 6 (n=158, 169)42
Extension Month 9 (n=151, 163)22
Extension Month 12 (n=152, 161)52
Extension Month 15 (n=143, 160)32
Extension Month 18 (n=148, 159)14
Extension Month 21 (n=144, 156)53
Extension Month 24 (n=140, 152)51
Extension Month 27 (n=136, 144)42
Extension Month 30 (n=135, 146)44
Extension Month 33 (n=127, 139)32
Extension Month 36 (n=105, 122)47
Extension Month 39 (n=52, 64)31
Extension Follow Up Month 3 (n=115, 101)32
SecondaryForced Vital Capacity (FVC)

Forced Vital Capacity (FVC) measured in liters (L).

Time frame:
Week -3 through Extension Follow-up Month 6 or End of Study
Reported as:
Mean · liters

No measurements were reported for this outcome.

SecondaryTotal Lung Capacity (TLC)

Total Lung Capacity measured in liters (L).

Time frame:
Week -3 through Extension Follow-up Month 6 or End of Study
Reported as:
Mean · liters

No measurements were reported for this outcome.

PrimaryAnnual Rate of Change in Forced Expiratory Volume in 1 Second (FEV1)

Annual rate of change in FEV1 calculated as slope over time \[visit\] for forced expiratory volume in 1 second measured as liters per year (L/yr).

Time frame:
Week -2 through Extension Follow-up Month 6 or end of study
Reported as:
Mean · liters per year

No measurements were reported for this outcome.

PrimaryAnnual Rate of Change in Carbon Monoxide Diffusion Capacity (DLco)

Annual rate of change in DLco calculated as slope over time (visit) measured as milliliters per minute per millimeters of hemoglobin per year (ml/min/mmHg/yr).

Time frame:
Week -2 through Extension Follow-up Month 6 or end of study
Reported as:
Mean · ml/min/mmHg/yr

No measurements were reported for this outcome.

SecondaryInsulin Antibodies

Median insulin antibodies at each visit measured in micro units per milliliter (microU/mL).

Time frame:
Baseline through Extension Month 39
Reported as:
Median · microU/mL
Insulin Antibodies
microU/mLInhaled InsulinSubcutaneous Insulin
Baseline (n=284, 283)4.50 (1.05 to 3514.00)4.10 (1.05 to 1324.00)
Week 3 (n=262, 260)7.50 (1.05 to 6056.00)3.60 (1.05 to 828.00)
Week 6 (n=267, 260)15.00 (1.05 to 12445.00)4.00 (1.05 to 1792.00)
Month 3 (n=271, 274)31.00 (1.05 to 4108.00)4.25 (1.05 to 876.00)
Week 18 (n=263, 271)49.00 (1.05 to 1968.00)4.40 (1.05 to 1012.00)
Month 6 (n=254, 268)88.50 (1.05 to 1420.00)5.10 (1.05 to 1352.00)
Month 9 (n=244, 262)134.50 (1.05 to 2776.00)4.95 (1.05 to 1608.00)
Month 12 (n=234, 258)142.50 (1.05 to 3156.00)4.90 (1.05 to 2192.00)
Month 15 (n=230, 250)109.50 (1.05 to 4380.00)4.70 (1.05 to 1360.00)
Month 18 (n=226, 233)91.00 (1.05 to 2390.00)4.40 (1.05 to 1655.00)
Month 21 (n=216, 228)59.50 (1.05 to 2575.00)3.85 (1.05 to 932.00)
Month 24 (n=212, 224)67.00 (1.05 to 2360.00)4.40 (1.05 to 1420.00)
Follow-up Month 1 (n=234, 209)41.50 (1.05 to 27286.00)4.20 (1.05 to 1285.00)
Follow-up Month 3 (n=245, 226)28.00 (1.05 to 8119.00)4.20 (1.05 to 382.00)
Follow-up Month 6 (n=239, 223)22.00 (1.05 to 5280.00)4.40 (1.05 to 1265.00)
Extension Month 1 (n=164, 176)37.50 (1.05 to 3985.00)4.50 (1.05 to 900.00)
Extension Month 3 (165, 177)45.00 (1.05 to 3405.00)4.40 (1.05 to 1260.00)
Extension Month 6 (n=162, 176)42.50 (1.05 to 3145.00)3.55 (1.05 to 720.00)
Extension Month 9 (n=154, 167)41.00 (1.05 to 2465.00)4.70 (1.05 to 873.00)
Extension Month 12 (n=155, 167)49.00 (1.05 to 3280.00)4.30 (1.05 to 1310.00)
Extension Month 15 (n=149, 163)43.00 (1.05 to 3955.00)4.50 (1.05 to 1330.00)
Extension Month 18 (n=149, 160)45.00 (1.05 to 10755.00)3.60 (1.05 to 1430.00)
Extension Month 21 (n=151, 157)44.00 (1.05 to 3200.00)3.60 (1.05 to 820.00)
Extension Month 24 (n=146, 153)42.50 (1.05 to 3920.00)4.40 (1.05 to 758.00)
Extension Month 27 (n=138, 148)35.00 (1.05 to 3040.00)6.35 (1.05 to 1121.00)
Extension Month 30 (n=139, 150)36.00 (1.05 to 3730.00)5.25 (1.05 to 1110.00)
Extension Month 33 (n=129, 142)35.00 (1.05 to 3980.00)4.30 (1.05 to 845.00)
Extension Month 36 (n=104, 132)30.50 (1.05 to 1477.00)3.65 (1.05 to 876.00)
Extension Month 39 (n=54, 66)25.50 (1.05 to 1750.00)1.58 (1.05 to 742.00)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaled Insulin—50/290 (17.2%)290/290 (100%)
Subcutaneous Insulin—65/290 (22.4%)289/290 (99.7%)
Most frequent serious events
Showing 10 of 94
Most frequent serious events
EventInhaled InsulinSubcutaneous Insulin
HypoglycaemiaMetabolism and nutrition disorders17/29026/290
Coronary artery diseaseCardiac disorders1/2904/290
Chest painGeneral disorders4/2902/290
CholelithiasisHepatobiliary disorders2/2901/290
AppendicitisInfections and infestations0/2902/290
PneumoniaInfections and infestations1/2902/290
Ankle fractureInjury, poisoning and procedural complications2/2900/290
HyperglycaemiaMetabolism and nutrition disorders2/2901/290
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2902/290
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2901/290
Most frequent other events
Showing 10 of 40
Most frequent other events
EventInhaled InsulinSubcutaneous Insulin
HypoglycaemiaMetabolism and nutrition disorders282/290285/290
CoughRespiratory, thoracic and mediastinal disorders130/29053/290
Upper respiratory tract infectionInfections and infestations124/290105/290
NasopharyngitisInfections and infestations96/290111/290
InfluenzaInfections and infestations84/29085/290
SinusitisInfections and infestations50/29047/290
Oropharyngeal painRespiratory, thoracic and mediastinal disorders35/29047/290
HeadacheNervous system disorders41/29046/290
TremorNervous system disorders42/29043/290
DiarrhoeaGastrointestinal disorders36/29028/290

Baseline characteristics

Age, Customized
Age, Customized(years)Inhaled InsulinSubcutaneous InsulinTotal
18 to 254853101
26 to 358196177
36 to 459471165
46 to 555248100
56 to 65152237
Sex: Female, Male
Sex: Female, Male(Participants)Inhaled InsulinSubcutaneous InsulinTotal
Female121129250
Male169161330
08

Study locations

73 sites
  • Pfizer Investigational Site
    Fullerton, California 92835, United States
  • Pfizer Investigational Site
    Long Beach, California 90806, United States
  • Pfizer Investigational Site
    Sacramento, California 95816, United States
  • Pfizer Investigational Site
    San Diego, California 92103, United States
  • Pfizer Investigational Site
    Santa Barbara, California 93105, United States
  • Pfizer Investigational Site
    Santa Rosa, California 95405, United States
  • Pfizer Investigational Site
    Tustin, California 92780, United States
  • Pfizer Investigational Site
    Walnut Creek, California 94598, United States
  • Pfizer Investigational Site
    Denver, Colorado 80220, United States
  • Pfizer Investigational Site
    Longmont, Colorado 80501, United States
  • Pfizer Investigational Site
    Hamden, Connecticut 06518, United States
  • Pfizer Investigational Site
    Madison, Connecticut 06443, United States
  • Pfizer Investigational Site
    Newark, Delaware 19713, United States
  • Pfizer Investigational Site
    Coral Gables, Florida 33134, United States
  • Pfizer Investigational Site
    Hollywood, Florida 33021, United States
  • Pfizer Investigational Site
    Miami, Florida 33136, United States
  • Pfizer Investigational Site
    Tallahassee, Florida 32308, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33401, United States
  • Pfizer Investigational Site
    Winter Park, Florida 32789, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60602, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60610, United States
  • Pfizer Investigational Site
    Wilmette, Illinois 60091, United States
  • Pfizer Investigational Site
    Bethesda, Maryland 20817, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63141, United States
  • Pfizer Investigational Site
    Butte, Montana 59701, United States
  • Pfizer Investigational Site
    New Hyde Park, New York 11042, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27713, United States
  • Pfizer Investigational Site
    Portland, Oregon 97210, United States
  • Pfizer Investigational Site
    Lansdale, Pennsylvania 19446, United States
  • Pfizer Investigational Site
    Dallas, Texas 75230, United States
  • Pfizer Investigational Site
    Dallas, Texas 75246, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Burlington, Vermont 05401, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23225, United States
  • Pfizer Investigational Site
    Renton, Washington 98057, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53209, United States
  • Pfizer Investigational Site
    Capital Federal, Buenos Aires C1120 AAF, Argentina
  • Pfizer Investigational Site
    Capital Federal, Buenos Aires C1181 ACH, Argentina
  • Pfizer Investigational Site
    Capital Federal, Buenos Aires C1405 DCS, Argentina
  • Pfizer Investigational Site
    Capital Federal, Buenos Aires C1427 AQR, Argentina
  • Pfizer Investigational Site
    Belo Horizonte, MG 30150-221, Brazil
  • Pfizer Investigational Site
    Curitiba, PR 80420-011, Brazil
  • Pfizer Investigational Site
    Porto Alegre, RS 90035-170, Brazil
  • Pfizer Investigational Site
    Porto Alegre, RS 90035-903, Brazil
  • Pfizer Investigational Site
    Campinas, SP 13083-900, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 01244-030, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 04231-030, Brazil
  • Pfizer Investigational Site
    São Paulo, SP 04020-041, Brazil
  • Pfizer Investigational Site
    Calgary, Alberta T2T 5C7, Canada
  • Pfizer Investigational Site
    Calgary, Alberta T3B 0M3, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T5J 3N4, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T6G 2C8, Canada
  • Pfizer Investigational Site
    Victoria, British Columbia V8R 1J8, Canada
  • Pfizer Investigational Site
    Winnepeg, Manitoba R3A 1R9, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R3E 3P4, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Pfizer Investigational Site
    Kingston, Ontario K7L 2V7, Canada
  • Pfizer Investigational Site
    London, Ontario N6A 4V2, Canada
  • Pfizer Investigational Site
    Mississauga, Ontario L5M 2V8, Canada
  • Pfizer Investigational Site
    Oakville, Ontario L6H 3P1, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K1H 1A2, Canada
  • Pfizer Investigational Site
    Thornhill, Ontario L4J 8L7, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M4R 2G4, Canada
  • Pfizer Investigational Site
    Laval, Quebec H7T 2P5, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H1T 2M4, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H3A 1A1, Canada
  • Pfizer Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Pfizer Investigational Site
    Mexico Df, Col Las Americas 01120, Mexico
  • Pfizer Investigational Site
    Mexico, DF 02990, Mexico
  • Pfizer Investigational Site
    Mexico, DF 14000, Mexico
  • Pfizer Investigational Site
    Monterrey, Nuevo Leon 64060, Mexico
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2002, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2005
First posted
Aug 29, 2005
Start
May 2002
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Jan 26, 2010
Last update
Feb 18, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00137046
Lead sponsor
Pfizer
First posted
Aug 29, 2005
Start date
May 2002
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Jan 26, 2010
Last update
Feb 18, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion